Additionally, while the molecular docking and MD simulations identified potential binding sites for FNC on Jagged1, the complexity of the cell surface and tumour microenvironment coupled with the use of only part of Jagged1’s extracellular domain in the analyses limited our ability to determine the exact in vivo binding site. The gene discussed is JAG1; the disease is neoplasm.